Table 4.

Unadjusted chronic measurements stratified by intervention arm

	Placebo (n = 30)				Blueberry (n = 30)				p-Value
	Baseline		6 weeks		Baseline		6 weeks
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Beck Depression Inventory-II	27.0	9.1	14.9	9.0	26.6	8.3	18.0	9.0	0.023*
Patient Health Quiestionnaire-9	14.4	3.8	7.9	4.2	14.5	3.6	9.9	4.9	0.040*
Generalized anxiety (GAD-7)	10.1	4.2	5.4	2.9	10.5	3.9	7.5	3.8	0.026*
Anhedonia (SHAPS)	19.75	6.8	11.5	6.3	20.0	4.9	14.4	5.9	0.029*
Perceived stress (PSS-10)	27.0	5.2	21.6	6.5	26.1	4.1	22.0	6.4	0.49
Positive affect	22.3	10.9	28.6	10.2	19.9	10.4	29.4	11.1	0.90
Negative affect	20.4	13.1	13.8	13.2	19.1	13.1	15.7	13.9	0.33
Calmness	5.1	2.4	5.8	2.6	4.8	2.0	5.3	2.5	0.82
Fatigue	7.8	4.5	7.3	3.9	8.5	3.7	7.4	3.7	0.76
Accuracy on switch trials, %	71.4	13.4	74.0	13.4	73.9	12.2	76.2	10.9	0.99
Reaction time on switch trials, ms	584	51	575	54	562	52	570	53	0.11
Negative interpretation bias, %	72.0	15.3	65.7	19.2	71.1	13.9	66.7	16.7	0.70
Accuracy on happy faces, %	87.7	10.5	88.2	9.9	85.7	14.4	85.7	11.8	0.55
Accuracy on angry faces, %	93.8	5.4	91.1	8.2	92.6	9.4	91.6	7.2	0.41
BDNF, ng/mL	33.5	7.3	33.0	7.1	31.3	7.8	31.5	9.1	0.59
hs-CRP, mg/L	1.15	1.30	1.48	1.66	1.69	2.06	1.83	1.86	0.57
IL-6, pg/mL	0.98	0.71	1.15	1.15	0.94	0.61	1.13	0.68	0.68
Superoxide dismutase, U/L	352	149	347	188	319	109	313	49	0.30
TBARS, mmol/L	531	492	705	675	469	441	739	584	0.99
Uric acid, μmol/L	301	69	300	83	305	68	315	90	0.24

p-Values refer to the effect of treatment in ANCOVAs adjusted for baseline, sex, FV intake, and the interactions of treatment with sex and FV intake. Missing values and outliers are excluded from the analyses. *denotes p < 0.05

BDNF brain-derived neurotrophic factor; hs-CRP high-sensitivity C-reactive protein; IL-6 interleukin-6; TBARS thiobarbituric acid reactive substances